French drug developer Nanobiotix prices upsized $99 million US IPO at $13.50 low end

Nanobiotix, a late-stage French developer of nanoparticle drugs that improve cancer radiotherapy, raised $99 million by offering 7.3 million ADS equivalents at $13.50, the low end of the range of $13.50 to $14.50. The company offered 0.8 million more ADS equivalents than anticipated. It originally planned to offer its securities at the as-converted close of its shares on the Euronext Paris (NANO), before setting the range to $13.50 to $14.50 on Wednesday. At pricing, the company commands a fully diluted market value of $502 million.

Nanobiotix plans to list on the Nasdaq under the symbol NBTX. Jefferies, Evercore ISI and UBS Investment Bank acted as lead managers on the deal.

The article French drug developer Nanobiotix prices upsized $99 million US IPO at $13.50 low end originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Renaissance Capital

Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

Learn More